Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Gastrointestinal inflammation? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Gastrointestinal inflammation have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

28
Reports of Gastrointestinal inflammation with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
4
Deaths
17
Hospitalizations

How Dangerous Is Gastrointestinal inflammation From PEMBROLIZUMAB?

Of the 28 reports, 4 (14.3%) resulted in death, 17 (60.7%) required hospitalization, and 1 (3.6%) were considered life-threatening.

Is Gastrointestinal inflammation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Gastrointestinal inflammation?

ADALIMUMAB (2,170) VEDOLIZUMAB (530) INFLIXIMAB (441) METHOTREXATE (218) RISANKIZUMAB-RZAA (157) USTEKINUMAB (141) PREDNISONE (121) CAPECITABINE (94) INFLIXIMAB-DYYB (92) HUMIRA (91)

Which PEMBROLIZUMAB Alternatives Have Lower Gastrointestinal inflammation Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Gastrointestinal inflammation Reports All Drugs Causing Gastrointestinal inflammation PEMBROLIZUMAB Demographics